Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02390674 | Ciclosporin to Reduce Reperfusion Injury in Primary PCI | PHASE2 | COMPLETED | 54 | — | — | Mar 1, 2015 | Nov 11, 2017 | Mar 29, 2018 | 1 | United Kingdom |
Change in infarct size 12 weeks post-PPCI as measured by cardiac MRI
| Arm | Type | Description |
|---|---|---|
| Ciclosporin | ACTIVE_COMPARATOR | Single intravenous administration of ciclosporin (2.5mg per kilogram body weight) immediately prior to reperfusion during primary percutaneous coronary intervention. Ciclosporin is dissolved in saline (maximum concentration 2.5mg per millilitre) |
| Saline | PLACEBO_COMPARATOR | Single intravenous administration of placebo (saline) immediately prior to reperfusion during primary percutaneous coronary intervention |
| Name | Type | Description |
|---|---|---|
| Ciclosporin | DRUG | Comparison between ciclosporin and placebo |
| Saline | DRUG | - |
Inclusion Criteria: * Patients presenting with acute myocardial infarction (STEMI) and undergoing primary percutaneous coronary intervention (PPCI) * Age above 18 years * Presenting within 6 hours of the onset chest pain and ST segment elevation. The culprit coronary artery has to be a major corona...